/ALZN
ALZN Stock - Alzamend Neuro, Inc.
Healthcare|BiotechnologyNASDAQ
$2.11-2.31%
$0.05 (-2.31%) • Dec 19
56
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.5
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $2.32
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ALZN
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$2.09 – $2.13
TARGET (TP)$2.43
STOP LOSS$1.94
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-0.25
52W High$11.70
52W Low$1.88
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-50,740 | $-50,740 | $-23,066 | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-4,496,824 | $-9,938,000 | $-14,870,000 | $-12,320,000 | $-4,952,000 |
| Net Income | $-4,514,853 | $-9,948,000 | $-14,878,000 | $-12,362,000 | $-5,047,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-11.32 | $-14.72 | $-2.25 | $-20.92 | $-0.89 |
Company Overview
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and AL002 that completed preclinical stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
ALZNBeat Rate
38%
Last 16 quarters
Avg Surprise
-331.1%
EPS vs Estimate
Beats / Misses
6/10
Last 12 quarters
Latest EPS
$-0.30
Q4 2025
EPS Surprise History
Q4 23
+6010.4%
$39.60vs$-0.67
Q1 24
-10587.5%
$-34.20vs$-0.32
Q3 24
-385.5%
$-13.35vs$-2.75
Q3 24
-372.7%
$-11.25vs$-2.38
Q4 24
+83.2%
$-3.60vs$-21.42
Q1 25
+34.5%
$-1.71vs$-2.61
Q3 25
+65.3%
$-1.28vs$-3.69
Q4 25
+63.9%
$-0.30vs$-0.83
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 9, 2026 | $-0.80 | — | — | — |
Q4 2025 | Dec 9, 2025 | $-0.83 | $-0.30 | +63.9% | ✓ BEAT |
Q3 2025 | Sep 10, 2025 | $-3.69 | $-1.28 | +65.3% | ✓ BEAT |
Q1 2025 | Mar 10, 2025 | $-2.61 | $-1.71 | +34.5% | ✓ BEAT |
Q4 2024 | Dec 11, 2024 | $-21.42 | $-3.60 | +83.2% | ✓ BEAT |
Q3 2024 | Sep 11, 2024 | $-2.38 | $-11.25 | -372.7% | ✗ MISS |
Q3 2024 | Jul 30, 2024 | $-2.75 | $-13.35 | -385.5% | ✗ MISS |
Q1 2024 | Mar 25, 2024 | $-0.32 | $-34.20 | -10587.5% | ✗ MISS |
Q4 2023 | Dec 15, 2023 | $-0.67 | $39.60 | +6010.4% | ✓ BEAT |
Q3 2023 | Sep 13, 2023 | $-47.23 | $-53.98 | -14.3% | ✗ MISS |
Q3 2023 | Jul 27, 2023 | $-30.36 | $-40.48 | -33.3% | ✗ MISS |
Q1 2023 | Mar 15, 2023 | $-0.04 | $-0.06 | -50.0% | ✗ MISS |
Q4 2022 | Dec 12, 2022 | $-0.02 | $-0.03 | -25.0% | ✗ MISS |
Q3 2022 | Sep 13, 2022 | $-0.07 | $-0.03 | +57.1% | ✓ BEAT |
Q3 2022 | Jul 19, 2022 | $-0.03 | $-0.04 | -33.3% | ✗ MISS |
Q1 2022 | Mar 15, 2022 | $-0.02 | $-0.03 | -50.0% | ✗ MISS |
Q4 2021 | Dec 13, 2021 | $-0.03 | $-0.04 | -60.0% | ✗ MISS |
Q3 2021 | Sep 13, 2021 | — | $-0.84 | — | — |
Q3 2021 | Jul 29, 2021 | — | $-0.51 | — | — |
Q1 2021 | Jan 31, 2021 | — | $-0.46 | — | — |
Latest News
Alzamend Neuro Q2 EPS $(0.30) Beats $(1.96) Estimate
📈 PositiveBenzinga•Dec 9, 2025, 10:37 PM
EXCLUSIVE: Alzamend Neuro Tells Benzinga 'Head-to-head studies of AL001 versus a marketed lithium carbonate product was conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in healthy subjects'
➖ NeutralBenzinga•Nov 19, 2025, 12:30 PM
EXCLUSIVE: Alzamend Neuro Tells Benzinga 'Topline data expected in first quarter of 2026'
➖ NeutralBenzinga•Nov 19, 2025, 12:30 PM
EXCLUSIVE: Alzamend Neuro Tells Benzinga Co. Announces Completion Of Clinical Portion Of Phase II Clinical Trial Of AL001 'Lithium In Brain' Study Conducted At Massachusetts General Hospital
📈 PositiveBenzinga•Nov 19, 2025, 12:29 PM
Ascendiant Capital Maintains Buy on Alzamend Neuro, Lowers Price Target to $42
➖ NeutralBenzinga•Sep 25, 2025, 12:02 PM
Alzamend Neuro Q1 EPS $(1.28) Misses $(0.69) Estimate
📉 NegativeBenzinga•Sep 10, 2025, 08:41 PM
Ascendiant Capital Maintains Buy on Alzamend Neuro, Lowers Price Target to $45
➖ NeutralBenzinga•Aug 21, 2025, 09:32 AM
Frequently Asked Questions about ALZN
What is ALZN's current stock price?
Alzamend Neuro, Inc. (ALZN) is currently trading at $2.11 per share. The stock has moved -2.31% today.
What is the analyst price target for ALZN?
No analyst price targets are currently available for this stock.
What sector is Alzamend Neuro, Inc. in?
Alzamend Neuro, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is ALZN's market cap?
Alzamend Neuro, Inc. has a market capitalization of $0.01 billion, making it a small-cap company.
Does ALZN pay dividends?
No, Alzamend Neuro, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACXP
Acurx Pharmaceuticals, Inc.
$3.33
Mkt Cap: $0.0B
ADIL
Adial Pharmaceuticals, Inc.
$0.24
Mkt Cap: $0.0B
APRE
Aprea Therapeutics, Inc.
$0.93
Mkt Cap: $0.0B
BCDA
BioCardia, Inc.
$1.27
Mkt Cap: $0.0B
CDIO
Cardio Diagnostics Holdings, Inc.
$3.23
Mkt Cap: $0.0B
CELZ
Creative Medical Technology Holdings, Inc.
$2.11
Mkt Cap: $0.0B
HCWB
HCW Biologics Inc.
$1.57
Mkt Cap: $0.0B
KPRX
Kiora Pharmaceuticals, Inc.
$2.16
Mkt Cap: $0.0B
NRSN
NeuroSense Therapeutics Ltd.
$0.81
Mkt Cap: $0.0B
PHIO
Phio Pharmaceuticals Corp.
$1.07
Mkt Cap: $0.0B
Explore stocks similar to ALZN for comparison